BC Week In Review | Aug 4, 2014
Clinical News

Albuterol multi-dose dry-powder inhaler regulatory update

Teva said FDA accepted for review an NDA for albuterol MDPI to treat and prevent bronchospasm in patients >=12 years old with reversible obstructive airway disease and to prevent exercise-induced bronchospasm in patients >=12 years...
Items per page:
1 - 1 of 1